Aktiesnakken — Juli 2011
-
arzerra nævnt under pipeline med 3 fase III forsøg
-
CLL (first line & relapsed), NHL FL og NHL DLBCL
-
22% qoq er altså godt
-
years not months
-
det er så lidt mindre fra 77 til 88 sorry 14%
-
88,6 mio dkk 17,7mio dkk royalty siger genmab selv
-
men det er noget afrundingshejs der gør det. faktisk er vi på 10,5 GP
-
men vi er nærmere deres forecast på 80 i royalties end vores. Men det er ok
-
markedet er ikke ligefrem gået på røven i benovelse
over tallene
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind